Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood. 2011;117(8):2358–65.
2. Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Bone Marrow Transplant. 2013;48(4):529–36.
3. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–89.
4. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.
5. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Bhatt VR et al. NCCN clinical practice guidelines in oncology (NCCN guidelines®) acute myeloid leukemia version 3.2018. Available at
https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
. Accessed 15 Oct 2018.